Effective Date:

Monday, December 01, 2014

Test Updates

In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled important changes regarding a number of tests we perform. Listed below are the types of changes that may be included in this notification, effective Monday, December 01, 2014

Test Changes - Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements.

Discontinued Tests - Tests being discontinued with alternate testing suggestions.

Please use this information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases.

If you have any questions about the information contained in this notification, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of NMS Labs and your assistance in implementing these changes.

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. NMS Labs does not assume responsibility for billing errors due to reliance on the CPT Codes listed in this document.

NMS LABS
3701 Welsh Road
Willow Grove, PA 19090
www.NMSLabs.com

Test Updates

Test Code	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
0512FL	Barbiturates Screen, Fluid			•					
0568FL	Benzodiazepines Screen, Fluid			•					
5113B	Buprenorphine and Metabolite - Free (Unconjugated) Confirmation, Blood			•	•			•	
52167B	Buprenorphine and Metabolite - Free (Unconjugated) Confirmation, Blood (Forensic)			•	•			•	
53167B	Buprenorphine and Metabolite - Free (Unconjugated) Confirmation, Blood (Forensic)			•	•			•	
52167FL	Buprenorphine and Metabolite - Free (Unconjugated) Confirmation, Fluid (Forensic)			•					
53167FL	Buprenorphine and Metabolite - Free (Unconjugated) Confirmation, Fluid (Forensic)			•					
5113SP	Buprenorphine and Metabolite - Free (Unconjugated) Confirmation, Serum/Plasma				•			•	
52167SP	Buprenorphine and Metabolite - Free (Unconjugated) Confirmation, Serum/Plasma (Forensic)				•			•	
53167SP	Buprenorphine and Metabolite - Free (Unconjugated) Confirmation, Serum/Plasma (Forensic)				•			•	
0802B	Buprenorphine and Metabolite - Free (Unconjugated) Screen, Blood		•	•	•	•			
0802SP	Buprenorphine and Metabolite - Free (Unconjugated) Screen, Serum/Plasma		•	•	•	•			
0801B	Buprenorphine and Metabolite - Free (Unconjugated), Blood			•	•			•	
0801SP	Buprenorphine and Metabolite - Free (Unconjugated), Serum/Plasma				•			•	
0885B	Butorphanol - Free (Unconjugated), Blood	•	•	•	•			•	
0885SP	Butorphanol - Free (Unconjugated), Serum/Plasma	•	•	•	•			•	
9356FL	Cannabinoids Screen, Fluid			•					
0606FL	Cocaine and Metabolites Screen, Fluid			•					
52375U	DMAA Confirmation, Urine			•					
0278U	DMAA, Urine			•					
8079B	Drug Impaired Driving/DRE Toxicology Low Dose Opiates Add-On, Blood (Forensic)								•
8079U	Drug Impaired Driving/DRE Toxicology Low Dose Opiates Add-On, Urine (Forensic)								•
8070B	Drug Impaired Driving/DRE Toxicology Panel (with Alcohol), Blood (Forensic)			•					

Test Updates

Test Code	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
8067B	Drug Impaired Driving/DRE Toxicology Panel (with Alcohol), Blood (Forensic) (CSA)			•					
8069B	Drug Impaired Driving/DRE Toxicology Panel (with Alcohol), Blood (Forensic) (CSA)			•					
8070SP	Drug Impaired Driving/DRE Toxicology Panel (with Alcohol), Serum/Plasma (Forensic)			•					
8068B	Drug Impaired Driving/DRE Toxicology Panel, Blood (CSA)			•					
8071B	Drug Impaired Driving/DRE Toxicology Panel, Blood (Forensic)			•					
8071SP	Drug Impaired Driving/DRE Toxicology Panel, Serum/Plasma (Forensic)			•					
8090B	Drug Impaired Driving/DRE Toxicology Panel, with Statement of Certainty®, Blood (Forensic)			•					
8091B	Drugs of Abuse (11 Panel) and Alcohol Screen, Blood (Forensic)			•					
8101B	Drugs of Abuse (11 Panel) and Alcohol Screen, Blood (Forensic)			•					
1858SP	Drugs of Abuse (11 Panel) and Alcohol Screen, Serum/Plasma			•					
8091SP	Drugs of Abuse (11 Panel) and Alcohol Screen, Serum/Plasma (Forensic)			•					
8101SP	Drugs of Abuse (11 Panel) and Alcohol Screen, Serum/Plasma (Forensic)			•					
10042B	Drugs of Abuse (8 Panel) Screen, Blood (CSA)		•	•	•				
1864B	Drugs of Abuse Screen (11 Panel), Blood			•					
8096B	Drugs of Abuse Screen (11 Panel), Blood (Forensic)			•					
1864SP	Drugs of Abuse Screen (11 Panel), Serum/Plasma			•					
1853SP	Drugs of Abuse Screen (11 Panel), Serum/Plasma (CSA)			•					
8096SP	Drugs of Abuse Screen (11 Panel), Serum/Plasma (Forensic)			•					
10011SP	Drugs of Abuse Screen (6 Panel), Serum/Plasma (CSA)			•					
1861B	Drugs of Abuse Screen (7 Panel), Blood			•					
1919FL	Electrolytes and Glucose Panel (Vitreous), Fluid (Forensic)							•	
1912SP	Embeda®, Serum/Plasma								•
1912U	Embeda®, Urine								•
9343B	Heroin Screen, Blood			•					
9343SP	Heroin Screen, Serum/Plasma			•					

Test Updates

Test Code	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
9332B	Hydrocodone Screen, Blood			•					
9332SP	Hydrocodone Screen, Serum/Plasma			•					
9522FL	Methamphetamine and Amphetamine Screen, Fluid			•					
3110B	Nalbuphine - Free (Unconjugated), Blood	•	•	•	•			•	
3110SP	Nalbuphine - Free (Unconjugated), Serum/Plasma	•	•	•	•			•	
3113B	Naloxone - Free (Unconjugated) Screen, Blood								•
3113FL	Naloxone - Free (Unconjugated) Screen, Fluid								•
3113SP	Naloxone - Free (Unconjugated) Screen, Serum/Plasma								•
3113TI	Naloxone - Free (Unconjugated) Screen, Tissue								•
3111B	Naloxone - Free (Unconjugated), Blood			•	•			•	
3111SP	Naloxone - Free (Unconjugated), Serum/Plasma				•			•	
52449B	Naltrexone - Free (Unconjugated) Confirmation, Blood (Forensic)			•	•			•	
52449SP	Naltrexone - Free (Unconjugated) Confirmation, Serum/Plasma (Forensic)			•	•			•	
3115B	Naltrexone and Metabolite - Free (Unconjugated) Screen, Blood								•
3115SP	Naltrexone and Metabolite - Free (Unconjugated) Screen, Serum/Plasma								•
3116B	Naltrexone and Metabolite - Free (Unconjugated), Blood			•	•			•	
3116SP	Naltrexone and Metabolite - Free (Unconjugated), Serum/Plasma				•			•	
3115U	Naltrexone and Metabolite - Total (Conjugated/Unconjugated) Screen, Urine								•
3237B	Opiates (Low Dose) - Free (Unconjugated) Screen, Blood								•
3237SP	Opiates (Low Dose) - Free (Unconjugated) Screen, Serum/Plasma								•
3237TI	Opiates (Low Dose) - Free (Unconjugated) Screen, Tissue								•
3237U	Opiates (Low Dose) - Total (Conjugated/Unconjugated) Screen, Urine								•
3236B	Opiates Screen, Blood			•					
3236SP	Opiates Screen, Serum/Plasma			•					
9132B	Oxycodone Screen, Blood			•					
9132SP	Oxycodone Screen, Serum/Plasma			•					
3532FL	Phencyclidine Screen, Fluid			•					

Test Updates

Test Code	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
8061B	Postmortem Toxicology - Basic w/o Alcohol, Blood (Forensic)			•	•				
8061TI	Postmortem Toxicology - Basic w/o Alcohol, Tissue					•			
8061U	Postmortem Toxicology - Basic w/o Alcohol, Urine (Forensic)			•		•			
8041B	Postmortem Toxicology - Basic with Vitreous Alcohol Confirmation, Blood (Forensic)			•	•	•			
10051B	Postmortem Toxicology - Basic with Vitreous Alcohol Confirmation, Blood (Forensic) (CSA)			•	•	•			
8056B	Postmortem Toxicology - Basic with Vitreous Alcohol Confirmation, Blood - University of MI (CSA)			•	•	•			
8051B	Postmortem Toxicology - Basic, Blood (Forensic)			•	•	•			
10055B	Postmortem Toxicology - Basic, Blood (Forensic) (CSA)		•	•	•	•			
8051FL	Postmortem Toxicology - Basic, Fluid (Forensic)			•		•			
8051SP	Postmortem Toxicology - Basic, Serum/Plasma (Forensic)			•		•			
8051TI	Postmortem Toxicology - Basic, Tissue (Forensic)					•			
8051U	Postmortem Toxicology - Basic, Urine (Forensic)			•		•			
9334FL	Propoxyphene Screen, Fluid			•					
4029B	Psilocybin as Psilocin (Qualitative), Blood		•						
4029SP	Psilocybin as Psilocin (Qualitative), Serum/Plasma		•						
4029U	Psilocybin as Psilocin (Qualitative), Urine		•						
4127B	Suboxone® - Free, Blood			•	•	•		•	
4127SP	Suboxone® - Free, Serum/Plasma				•	•			
54334B	Synthetic Opioids - Free (Unconjugated) Confirmation (Drug Impaired Driving/DRE Toxicology), Blood (Forensic)	•	•	•	•				
54334SP	Synthetic Opioids - Free (Unconjugated) Confirmation (Drug Impaired Driving/DRE Toxicology), Serum/Plasma (Forensic)	•	•	•	•				
52092B	Synthetic Opioids - Free (Unconjugated) Confirmation, Blood (Forensic)	•		•	•	•		•	
52407B	Synthetic Opioids - Free (Unconjugated) Confirmation, Blood (Forensic)	•		•	•			•	
52448B	Synthetic Opioids - Free (Unconjugated) Confirmation, Blood (Forensic)	•		•	•			•	
53092B	Synthetic Opioids - Free (Unconjugated) Confirmation, Blood (Forensic)	•		•	•	•		•	

Effective Date:

Monday, December 01, 2014

Test Updates

Test Code	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
52196B	Synthetic Opioids - Free (Unconjugated) Confirmation, Blood (Forensic) (CSA)	•		•	•			•	
52092FL	Synthetic Opioids - Free (Unconjugated) Confirmation, Fluid (Forensic)	•		•		•			
53092FL	Synthetic Opioids - Free (Unconjugated) Confirmation, Fluid (Forensic)	•		•		•			
52092SP	Synthetic Opioids - Free (Unconjugated) Confirmation, Serum/Plasma (Forensic)	•			•	•		•	
52407SP	Synthetic Opioids - Free (Unconjugated) Confirmation, Serum/Plasma (Forensic)	•		•	•			•	
52448SP	Synthetic Opioids - Free (Unconjugated) Confirmation, Serum/Plasma (Forensic)	•		•	•			•	
53092SP	Synthetic Opioids - Free (Unconjugated) Confirmation, Serum/Plasma (Forensic)	•			•	•		•	
4303SP	Talwin® Nx, Serum/Plasma				•				

Test Updates

Test Changes

0512FL Barbiturates Screen, Fluid

Summary of Changes:	Specimen Requirements were changed.

Specimen Requirements:	4 mL Fluid
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None

0568FL Benzodiazepines Screen, Fluid

Summary of Changes:	Specimen Requirements were changed.

Specimen Requirements:	4 mL Fluid
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None

52167B Buprenorphine and Metabolite - Free (Unconjugated) Confirmation, Blood (Forensic)

Summary of Changes:	Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Specimen Requirements (Rejection Criteria) were changed. Stability was changed. Reference Comment was changed.

Specimen Requirements:	2 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Stability:	Room Temperature: 14 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (83925): Buprenorphine - Free, Norbuprenorphine - Free

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Buprenorphine - Free	ng/mL	Maximum plasma buprenorphine concentrations in patients maintained on varying buprenorphine doses were: 2 mg/day: 0.3 +/- 0.1 ng/mL 16 mg/day: 6.3 +/- 0.9 ng/mL 32 mg/day: 13 +/- 4.2 ng/mL The blood to plasma ratio of buprenorphine is approximately 1.0 - 1.4.
Norbuprenorphine - Free	ng/mL	Maximum plasma norbuprenorphine concentrations in patients maintained on varying buprenorphine doses were: 2 mg/day: 0.7 +/- 0.2 ng/mL 16 mg/day: 5.4 +/- 1.3 ng/mL 32 mg/day: 14 +/- 2.9 ng/mL The blood to plasma ratio for norbuprenorphine is not known.

53167B Buprenorphine and Metabolite - Free (Unconjugated) Confirmation, Blood (Forensic)

Summary of Changes:
Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.
Reference Comment was changed.

Specimen Requirements: 2 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 14 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code): LC-MS/MS (83925): Buprenorphine - Free, Norbuprenorphine - Free

Compound Name	Units	Reference Comment
Buprenorphine - Free	ng/mL	Maximum plasma buprenorphine concentrations in patients maintained on varying buprenorphine doses were: 2 mg/day: 0.3 +/- 0.1 ng/mL 16 mg/day: 6.3 +/- 0.9 ng/mL 32 mg/day: 13 +/- 4.2 ng/mL The blood to plasma ratio of buprenorphine is approximately 1.0 - 1.4.

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Norbuprenorphine - Free	ng/mL	Maximum plasma norbuprenorphine concentrations in patients maintained on varying buprenorphine doses were: 2 mg/day: 0.7 +/- 0.2 ng/mL 16 mg/day: 5.4 +/- 1.3 ng/mL 32 mg/day: 14 +/- 2.9 ng/mL The blood to plasma ratio for norbuprenorphine is not known.

5113B Buprenorphine and Metabolite - Free (Unconjugated) Confirmation, Blood

Summary of Changes:
Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.
Reference Comment was changed.

Specimen Requirements: 2 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 14 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code): LC-MS/MS (83925): Buprenorphine - Free, Norbuprenorphine - Free

Compound Name	Units	Reference Comment
Buprenorphine - Free	ng/mL	Maximum plasma buprenorphine concentrations in patients maintained on varying buprenorphine doses were: 2 mg/day: 0.3 +/- 0.1 ng/mL 16 mg/day: 6.3 +/- 0.9 ng/mL 32 mg/day: 13 +/- 4.2 ng/mL The blood to plasma ratio of buprenorphine is approximately 1.0 - 1.4.

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Norbuprenorphine - Free	ng/mL	Maximum plasma norbuprenorphine concentrations in patients maintained on varying buprenorphine doses were: 2 mg/day: 0.7 +/- 0.2 ng/mL 16 mg/day: 5.4 +/- 1.3 ng/mL 32 mg/day: 14 +/- 2.9 ng/mL The blood to plasma ratio for norbuprenorphine is not known.

52167FL Buprenorphine and Metabolite - Free (Unconjugated) Confirmation, Fluid (Forensic)

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.

Specimen Requirements: 2 mL Fluid
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None

53167FL Buprenorphine and Metabolite - Free (Unconjugated) Confirmation, Fluid (Forensic)

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.

Specimen Requirements: 2 mL Fluid
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None

52167SP Buprenorphine and Metabolite - Free (Unconjugated) Confirmation, Serum/Plasma (Forensic)

Summary of Changes: Stability was changed.
Reference Comment was changed.

Stability: Room Temperature: 29 day(s)
Refrigerated: 29 day(s)
Frozen (-20 °C): 29 day(s)
Scope of Analysis: Method (CPT Code): LC-MS/MS (83925): Buprenorphine - Free, Norbuprenorphine - Free

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Buprenorphine - Free	ng/mL	Maximum plasma buprenorphine concentrations in patients maintained on varying buprenorphine doses were: 2 mg/day: 0.3 +/- 0.1 ng/mL 16 mg/day: 6.3 +/- 0.9 ng/mL 32 mg/day: 13 +/- 4.2 ng/mL
Norbuprenorphine - Free	ng/mL	Maximum plasma norbuprenorphine concentrations in patients maintained on varying buprenorphine doses were: 2 mg/day: 0.7 +/- 0.2 ng/mL 16 mg/day: 5.4 +/- 1.3 ng/mL 32 mg/day: 14 +/- 2.9 ng/mL

53167SP Buprenorphine and Metabolite - Free (Unconjugated) Confirmation, Serum/Plasma (Forensic)

Summary of Changes: Stability was changed.
Reference Comment was changed.

Stability: Room Temperature: 29 day(s)
Refrigerated: 29 day(s)
Frozen (-20 °C): 29 day(s)

Scope of Analysis: LC-MS/MS (83925): Buprenorphine - Free, Norbuprenorphine - Free
Method (CPT Code)

Compound Name	Units	Reference Comment
Buprenorphine - Free	ng/mL	Maximum plasma buprenorphine concentrations in patients maintained on varying buprenorphine doses were: 2 mg/day: 0.3 +/- 0.1 ng/mL 16 mg/day: 6.3 +/- 0.9 ng/mL 32 mg/day: 13 +/- 4.2 ng/mL
Norbuprenorphine - Free	ng/mL	Maximum plasma norbuprenorphine concentrations in patients maintained on varying buprenorphine doses were: 2 mg/day: 0.7 +/- 0.2 ng/mL 16 mg/day: 5.4 +/- 1.3 ng/mL 32 mg/day: 14 +/- 2.9 ng/mL

5113SP Buprenorphine and Metabolite - Free (Unconjugated) Confirmation, Serum/Plasma

Summary of Changes: Stability was changed.
Reference Comment was changed.

Stability: Room Temperature: 29 day(s)
Refrigerated: 29 day(s)
Frozen (-20 °C): 29 day(s)

Scope of Analysis: LC-MS/MS (83925): Buprenorphine - Free, Norbuprenorphine - Free
Method (CPT Code)

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Buprenorphine - Free	ng/mL	Maximum plasma buprenorphine concentrations in patients maintained on varying buprenorphine doses were: 2 mg/day: 0.3 +/- 0.1 ng/mL 16 mg/day: 6.3 +/- 0.9 ng/mL 32 mg/day: 13 +/- 4.2 ng/mL
Norbuprenorphine - Free	ng/mL	Maximum plasma norbuprenorphine concentrations in patients maintained on varying buprenorphine doses were: 2 mg/day: 0.7 +/- 0.2 ng/mL 16 mg/day: 5.4 +/- 1.3 ng/mL 32 mg/day: 14 +/- 2.9 ng/mL

0802B Buprenorphine and Metabolite - Free (Unconjugated) Screen, Blood

Summary of Changes:
Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.
Scope of Analysis was changed.
Buprenorphine / Metabolite was added.
Methods/CPT Codes were changed [ELISA (80101)]
Buprenorphine - Free and Norbuprenorphine - Free were removed.

Specimen Requirements: 2 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 14 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code): ELISA (80101): Buprenorphine / Metabolite

Compound Name	Units	Reference Comment
Buprenorphine / Metabolite	ng/mL	Maximum plasma buprenorphine concentrations in patients maintained on varying buprenorphine doses were: 2 mg/day: 0.3 +/- 0.1 ng/mL 16 mg/day: 6.3 +/- 0.9 ng/mL 32 mg/day: 13 +/- 4.2 ng/mL The blood to plasma ratio of buprenorphine is approximately 1.0 - 1.4.

0802SP Buprenorphine and Metabolite - Free (Unconjugated) Screen, Serum/Plasma

Test Updates

Test Changes

Summary of Changes:	Specimen Requirements were changed. Stability was changed. Scope of Analysis was changed. Buprenorphine / Metabolite was added. Methods/CPT Codes were changed [ELISA (80101)] Buprenorphine - Free and Norbuprenorphine - Free were removed.

Specimen Requirements:	3 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: 29 day(s) Refrigerated: 29 day(s) Frozen (-20 °C): 29 day(s)
Scope of Analysis: Method (CPT Code)	ELISA (80101): Buprenorphine / Metabolite

Compound Name	Units	Reference Comment
Buprenorphine / Metabolite	ng/mL	Maximum plasma buprenorphine concentrations in patients maintained on varying buprenorphine doses were: 2 mg/day: 0.3 +/- 0.1 ng/mL 16 mg/day: 6.3 +/- 0.9 ng/mL 32 mg/day: 13 +/- 4.2 ng/mL

0801B Buprenorphine and Metabolite - Free (Unconjugated), Blood

Summary of Changes:	Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Specimen Requirements (Rejection Criteria) were changed. Stability was changed. Reference Comment was changed.

Specimen Requirements:	2 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None

Test Updates

Test Changes

Stability: Room Temperature: 14 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: LC-MS/MS (83925): Buprenorphine - Free, Norbuprenorphine - Free
Method (CPT Code)

Compound Name	Units	Reference Comment
Buprenorphine - Free	ng/mL	Maximum plasma buprenorphine concentrations in patients maintained on varying buprenorphine doses were: 2 mg/day: 0.3 +/- 0.1 ng/mL 16 mg/day: 6.3 +/- 0.9 ng/mL 32 mg/day: 13 +/- 4.2 ng/mL The blood to plasma ratio of buprenorphine is approximately 1.0 - 1.4.
Norbuprenorphine - Free	ng/mL	Maximum plasma norbuprenorphine concentrations in patients maintained on varying buprenorphine doses were: 2 mg/day: 0.7 +/- 0.2 ng/mL 16 mg/day: 5.4 +/- 1.3 ng/mL 32 mg/day: 14 +/- 2.9 ng/mL The blood to plasma ratio for norbuprenorphine is not known.

0801SP Buprenorphine and Metabolite - Free (Unconjugated), Serum/Plasma

Summary of Changes: Stability was changed.
Reference Comment was changed.

Stability: Room Temperature: 29 day(s)
Refrigerated: 29 day(s)
Frozen (-20 °C): 29 day(s)
Scope of Analysis: LC-MS/MS (83925): Buprenorphine - Free, Norbuprenorphine - Free
Method (CPT Code)

Compound Name	Units	Reference Comment
Buprenorphine - Free	ng/mL	Maximum plasma buprenorphine concentrations in patients maintained on varying buprenorphine doses were: 2 mg/day: 0.3 +/- 0.1 ng/mL 16 mg/day: 6.3 +/- 0.9 ng/mL 32 mg/day: 13 +/- 4.2 ng/mL
Norbuprenorphine - Free	ng/mL	Maximum plasma norbuprenorphine concentrations in patients maintained on varying buprenorphine doses were: 2 mg/day: 0.7 +/- 0.2 ng/mL 16 mg/day: 5.4 +/- 1.3 ng/mL 32 mg/day: 14 +/- 2.9 ng/mL

Test Updates

Test Changes

0885B Butorphanol - Free (Unconjugated), Blood

Summary of Changes: Test Name was changed.
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (83925)]

Specimen Requirements: 2 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code): LC-MS/MS (83925): Butorphanol - Free

Compound Name	Units	Reference Comment
Butorphanol - Free	ng/mL	Peak plasma concentrations following 1 to 2 mg doses of butorphanol by intravenous, intramuscular or intranasal routes range from 1 to 4 ng/mL. The blood to plasma ratio of butorphanol is approximately 1.2.

0885SP Butorphanol - Free (Unconjugated), Serum/Plasma

Summary of Changes: Test Name was changed.
Specimen Requirements were changed.
Specimen Requirements (Special Handling) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (83925)]

Specimen Requirements: 2 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).

Test Updates

Test Changes

Stability: Room Temperature: 29 day(s)
Refrigerated: 29 day(s)
Frozen (-20 °C): 29 day(s)
Scope of Analysis: LC-MS/MS (83925): Butorphanol - Free
Method (CPT Code)

Compound Name	Units	Reference Comment
Butorphanol - Free	ng/mL	Peak plasma concentrations following 1 to 2 mg doses of butorphanol by intravenous, intramuscular or intranasal routes range from 1 to 4 ng/mL.

9356FL Cannabinoids Screen, Fluid

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements: 4 mL Fluid
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None

0606FL Cocaine and Metabolites Screen, Fluid

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements: 4 mL Fluid
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None

52375U DMAA Confirmation, Urine

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements: 1 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None

Test Updates

Test Changes

0278U DMAA, Urine

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements: 1 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None

8067B Drug Impaired Driving/DRE Toxicology Panel (with Alcohol), Blood (Forensic) (CSA)

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements: 6 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: Collect sample using alcohol free skin preparation.
Rejection Criteria: Received Room Temperature.

8069B Drug Impaired Driving/DRE Toxicology Panel (with Alcohol), Blood (Forensic) (CSA)

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements: 6 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: Collect sample using alcohol free skin preparation.
Rejection Criteria: Received Room Temperature.

8070B Drug Impaired Driving/DRE Toxicology Panel (with Alcohol), Blood (Forensic)

Summary of Changes: Specimen Requirements were changed.

Test Updates

Test Changes

Specimen Requirements: 6 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: Collect sample using alcohol free skin preparation.
Rejection Criteria: Received Room Temperature.

8070SP Drug Impaired Driving/DRE Toxicology Panel (with Alcohol), Serum/Plasma (Forensic)

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements: 6 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Gray top tube (Sodium Fluoride / Potassium Oxalate).
Collect sample using alcohol free skin preparation. Promptly centrifuge and separate Serum or Plasma into an plastic screw capped vial using approved guidelines.
Rejection Criteria: Received Room Temperature. Polymer gel separation tube (SST or PST).

8068B Drug Impaired Driving/DRE Toxicology Panel, Blood (CSA)

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements: 5 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: Received Room Temperature.

8071B Drug Impaired Driving/DRE Toxicology Panel, Blood (Forensic)

Summary of Changes: Specimen Requirements were changed.

Test Updates

Test Changes

Specimen Requirements:	5 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	Received Room Temperature.

8071SP Drug Impaired Driving/DRE Toxicology Panel, Serum/Plasma (Forensic)

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements:	5 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Gray top tube (Sodium Fluoride / Potassium Oxalate). Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Received Room Temperature. Polymer gel separation tube (SST or PST).

8090B Drug Impaired Driving/DRE Toxicology Panel, with Statement of Certainty®, Blood (Forensic)

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements:	6 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	Collect sample using alcohol free skin preparation.
Rejection Criteria:	Received Room Temperature.

8091B Drugs of Abuse (11 Panel) and Alcohol Screen, Blood (Forensic)

Summary of Changes: Specimen Requirements were changed.

Test Updates

Test Changes

Specimen Requirements: 6 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: Collect sample using alcohol free skin preparation.
Rejection Criteria: Received Room Temperature.

8101B Drugs of Abuse (11 Panel) and Alcohol Screen, Blood (Forensic)

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements: 6 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: Collect sample using alcohol free skin preparation.
Rejection Criteria: Received Room Temperature.

8091SP Drugs of Abuse (11 Panel) and Alcohol Screen, Serum/Plasma (Forensic)

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements: 6 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Gray top tube (Sodium Fluoride / Potassium Oxalate).
Collect sample using alcohol free skin preparation. Promptly centrifuge and separate Serum or Plasma into an plastic screw capped vial using approved guidelines.
Rejection Criteria: Received Room Temperature. Polymer gel separation tube (SST or PST).

8101SP Drugs of Abuse (11 Panel) and Alcohol Screen, Serum/Plasma (Forensic)

Summary of Changes: Specimen Requirements were changed.

Test Updates

Test Changes

Specimen Requirements:	6 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Submit with Chain of Custody. Serum: Collect sample in Red top tube. Plasma: Collect sample in Gray top tube (Sodium Fluoride / Potassium Oxalate). Collect sample using alcohol free skin preparation. Promptly centrifuge and separate Serum or Plasma into an plastic screw capped vial using approved guidelines.
Rejection Criteria:	Received Room Temperature. Polymer gel separation tube (SST or PST).

1858SP Drugs of Abuse (11 Panel) and Alcohol Screen, Serum/Plasma

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements:	6 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Collect sample using alcohol free skin preparation. Promptly centrifuge and separate Serum or Plasma into an plastic screw capped vial using approved guidelines.
Rejection Criteria:	Received Room Temperature. Polymer gel separation tube (SST or PST).

10042B Drugs of Abuse (8 Panel) Screen, Blood (CSA)

Summary of Changes: Specimen Requirements were changed.
Stability was changed.
Methods/CPT Codes were changed [ELISA (80101x8)]

Specimen Requirements:	4 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	Submit with Chain of Custody.
Rejection Criteria:	Received Room Temperature.
Stability:	Room Temperature: 1 day(s) Refrigerated: 10 day(s) Frozen (-20 °C): Undetermined
Scope of Analysis: Method (CPT Code)	ELISA (80101x8): Opiates, Cocaine / Metabolites, Benzodiazepines, Amphetamines, Methadone, Methamphetamine, Oxycodone, Buprenorphine / Metabolite

8096B Drugs of Abuse Screen (11 Panel), Blood (Forensic)

Test Updates

Test Changes

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements: 5 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: Received Room Temperature.

1864B Drugs of Abuse Screen (11 Panel), Blood

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements: 5 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: Received Room Temperature.

1853SP Drugs of Abuse Screen (11 Panel), Serum/Plasma (CSA)

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements: 2 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Received Room Temperature. Polymer gel separation tube (SST or PST).

8096SP Drugs of Abuse Screen (11 Panel), Serum/Plasma (Forensic)

Summary of Changes: Specimen Requirements were changed.

Test Updates

Test Changes

Specimen Requirements: 5 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Gray top tube (Sodium Fluoride / Potassium Oxalate).
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Received Room Temperature. Polymer gel separation tube (SST or PST).

1864SP Drugs of Abuse Screen (11 Panel), Serum/Plasma

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements: 5 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Gray top tube (Sodium Fluoride / Potassium Oxalate).
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Received Room Temperature. Polymer gel separation tube (SST or PST).

10011SP Drugs of Abuse Screen (6 Panel), Serum/Plasma (CSA)

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements: 2 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Received Room Temperature. Polymer gel separation tube (SST or PST).

1861B Drugs of Abuse Screen (7 Panel), Blood

Summary of Changes: Specimen Requirements were changed.

Test Updates

Test Changes

Specimen Requirements: 5 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: Received Room Temperature.

1919FL Electrolytes and Glucose Panel (Vitreous), Fluid (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis: Colorimetry (82570): Creatinine (Vitreous Fluid)
Method (CPT Code) Chemistry Analyzer (84302,83520,82438,84520,82945): Sodium (Vitreous Fluid), Potassium (Vitreous Fluid), Chloride (Vitreous Fluid), Glucose (Vitreous Fluid), Urea Nitrogen (Vitreous Fluid)

Compound Name	Units	Reference Comment
Potassium (Vitreous Fluid)	mmol/L	Normal: <15 mmol/L Quantitative results for Potassium will be affected if performed on gray top tubes since these collection tubes contain potassium oxalate.

9343B Heroin Screen, Blood

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements: 2 mL Blood
Transport Temperature: Frozen
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: Received Room Temperature. Received Refrigerated.

9343SP Heroin Screen, Serum/Plasma

Summary of Changes: Specimen Requirements were changed.

Test Updates

Test Changes

Specimen Requirements:	2 mL Serum or Plasma
Transport Temperature:	Frozen
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Gray top tube (Sodium Fluoride / Potassium Oxalate). Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Received Room Temperature. Received Refrigerated. Polymer gel separation tube (SST or PST).

9332B Hydrocodone Screen, Blood

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements:	2 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None

9332SP Hydrocodone Screen, Serum/Plasma

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements:	2 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Received Room Temperature. Polymer gel separation tube (SST or PST).

9522FL Methamphetamine and Amphetamine Screen, Fluid

Summary of Changes: Specimen Requirements were changed.

Test Updates

Test Changes

Specimen Requirements: 4 mL Fluid
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None

3110B Nalbuphine - Free (Unconjugated), Blood

Summary of Changes: Test Name was changed.
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (83925)]

Specimen Requirements: 2 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code): LC-MS/MS (83925): Nalbuphine - Free

Compound Name	Units	Reference Comment
Nalbuphine - Free	ng/mL	The average peak plasma concentration was 53 ng/mL nalbuphine 5 minutes after a 10 mg intravenous dose. The blood to plasma ratio of nalbuphine is approximately 0.9 to 1.0.

3110SP Nalbuphine - Free (Unconjugated), Serum/Plasma

Summary of Changes: Test Name was changed.
Specimen Requirements were changed.
Specimen Requirements (Special Handling) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (83925)]

Test Updates

Test Changes

Specimen Requirements:	2 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: 29 day(s) Refrigerated: 29 day(s) Frozen (-20 °C): 29 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (83925): Nalbuphine - Free

Compound Name	Units	Reference Comment
Nalbuphine - Free	ng/mL	The average peak plasma concentration was 53 ng/mL nalbuphine 5 minutes after a 10 mg intravenous dose.

3111B Naloxone - Free (Unconjugated), Blood

Summary of Changes:	Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Stability was changed. Reference Comment was changed.

Specimen Requirements:	2 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Stability:	Room Temperature: 14 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (83925): Naloxone - Free

Compound Name	Units	Reference Comment
Naloxone - Free	ng/mL	Intravenous injection of 0.4 mg naloxone produced an average peak plasma concentration of 10 +/- 1 ng/mL at two minutes. The blood to plasma ratio of naloxone is not known.

Test Updates

Test Changes

3111SP Naloxone - Free (Unconjugated), Serum/Plasma

Summary of Changes: Stability was changed.
Reference Comment was changed.

Stability: Room Temperature: 13 day(s)
Refrigerated: 29 day(s)
Frozen (-20 °C): 29 day(s)

Scope of Analysis: LC-MS/MS (83925): Naloxone - Free
Method (CPT Code)

Compound Name	Units	Reference Comment
Naloxone - Free	ng/mL	Intravenous injection of 0.4 mg naloxone produced an average peak plasma concentration of 10 +/- 1 ng/mL at two minutes.

52449B Naltrexone - Free (Unconjugated) Confirmation, Blood (Forensic)

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Reference Comment was changed.

Specimen Requirements: 2 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 14 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: LC-MS/MS (83925): Naltrexone - Free
Method (CPT Code)

Compound Name	Units	Reference Comment
Naltrexone - Free	ng/mL	The peak plasma concentrations at approximately one hour following a single oral dose of naltrexone were: 9 (+/- 5) ng/mL after 50 mg 20 (+/- 18) ng/mL after 100 mg 36 (+/- 20) ng/mL after 200 mg The average peak plasma concentration of naltrexone was 28 ng/mL following four doses of 380 mg naltrexone given by depot intramuscular injection every 28 days. The blood to plasma ratio of naltrexone is approximately 0.9.

Test Updates

Test Changes

52449SP Naltrexone - Free (Unconjugated) Confirmation, Serum/Plasma (Forensic)

Summary of Changes:	Specimen Requirements were changed. Stability was changed. Reference Comment was changed.

Specimen Requirements:	2 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: 13 day(s) Refrigerated: 29 day(s) Frozen (-20 °C): 29 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (83925): Naltrexone - Free

Compound Name	Units	Reference Comment
Naltrexone - Free	ng/mL	The peak plasma concentrations at approximately one hour following a single oral dose of naltrexone were: 9 (+/- 5) ng/mL after 50 mg 20 (+/- 18) ng/mL after 100 mg 36 (+/- 20) ng/mL after 200 mg The average peak plasma concentration of naltrexone was 28 ng/mL following four doses of 380 mg naltrexone given by depot intramuscular injection every 28 days.

3116B Naltrexone and Metabolite - Free (Unconjugated), Blood

Summary of Changes:	Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Stability was changed. Reference Comment was changed.

Specimen Requirements:	2 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None

Test Updates

Test Changes

Stability: Room Temperature: 14 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: LC-MS/MS (83925): Naltrexone - Free, 6-Beta-Naltrexol - Free
Method (CPT Code)

Compound Name	Units	Reference Comment
Naltrexone - Free	ng/mL	The peak plasma concentrations at approximately one hour following a single oral dose of naltrexone were: 9 (+/- 5) ng/mL after 50 mg 20 (+/- 18) ng/mL after 100 mg 36 (+/- 20) ng/mL after 200 mg The average peak plasma concentration of naltrexone was 28 ng/mL following four doses of 380 mg naltrexone given by depot intramuscular injection every 28 days. The blood to plasma ratio of naltrexone is approximately 0.9.
6-Beta-Naltrexol - Free	ng/mL	The peak plasma concentrations of 6-beta naltrexol at approximately one hour following a single oral dose of naltrexone were: 99 (+/- 30) ng/mL after 50 mg 210 (+/- 78) ng/mL after 100 mg 440 (+/- 140) ng/mL after 200 mg The average peak plasma concentration of 6-beta-naltrexol was 34 ng/mL following four doses of 380 mg naltrexone given by depot intramuscular injection every 28 days. The blood to plasma ratio of 6-beta-naltrexol is approximately 0.5.

3116SP Naltrexone and Metabolite - Free (Unconjugated), Serum/Plasma

Summary of Changes: Stability was changed.
Reference Comment was changed.

Stability: Room Temperature: 13 day(s)
Refrigerated: 29 day(s)
Frozen (-20 °C): 29 day(s)
Scope of Analysis: LC-MS/MS (83925): Naltrexone - Free, 6-Beta-Naltrexol - Free
Method (CPT Code)

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Naltrexone - Free	ng/mL	The peak plasma concentrations at approximately one hour following a single oral dose of naltrexone were: 9 (+/- 5) ng/mL after 50 mg 20 (+/- 18) ng/mL after 100 mg 36 (+/- 20) ng/mL after 200 mg The average peak plasma concentration of naltrexone was 28 ng/mL following four doses of 380 mg naltrexone given by depot intramuscular injection every 28 days.
6-Beta-Naltrexol - Free	ng/mL	The peak plasma concentrations of 6-beta naltrexol at approximately one hour following a single oral dose of naltrexone were: 99 (+/- 30) ng/mL after 50 mg 210 (+/- 78) ng/mL after 100 mg 440 (+/- 140) ng/mL after 200 mg The average peak plasma concentration of 6-beta-naltrexol was 34 ng/mL following four doses of 380 mg naltrexone given by depot intramuscular injection every 28 days.

3236B Opiates Screen, Blood

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements: 2 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None

3236SP Opiates Screen, Serum/Plasma

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements: 2 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Received Room Temperature. Polymer gel separation tube (SST or PST).

Test Updates

Test Changes

9132B Oxycodone Screen, Blood

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements:	2 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None

9132SP Oxycodone Screen, Serum/Plasma

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements:	2 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Received Room Temperature. Polymer gel separation tube (SST or PST).

3532FL Phencyclidine Screen, Fluid

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements:	5 mL Fluid
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None

8061B Postmortem Toxicology - Basic w/o Alcohol, Blood (Forensic)

Summary of Changes: Specimen Requirements were changed.
Stability was changed.

Test Updates

Test Changes

Specimen Requirements: 5 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: Submit with Chain of Custody.
Rejection Criteria: Received Room Temperature.
Stability: Room Temperature: 1 day(s)
Refrigerated: 10 day(s)
Frozen (-20 °C): Undetermined

8061TI Postmortem Toxicology - Basic w/o Alcohol, Tissue

Summary of Changes: Scope of Analysis was changed.
Order of Reporting was changed.

Scope of Analysis: Method (CPT Code): ELISA (80103, 80101x12): Opiates, Cocaine / Metabolites, Benzodiazepines, Cannabinoids, Amphetamines, Barbiturates, Methadone, Phencyclidine, Propoxyphene, Methamphetamine, Oxycodone, Buprenorphine / Metabolite

8061U Postmortem Toxicology - Basic w/o Alcohol, Urine (Forensic)

Summary of Changes: Specimen Requirements were changed.
Scope of Analysis was changed.
Fentanyl was added.
Propoxyphene was removed.

Specimen Requirements: 10 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Scope of Analysis: Method (CPT Code): EIA (80101x8): Opiates, Cocaine / Metabolites, Benzodiazepines, Cannabinoids, Barbiturates, Methadone, Phencyclidine, Oxycodone
IA (80101): Buprenorphine / Metabolite
EIA (80101x2): Amphetamines, MDMA
ELISA (80101): Fentanyl

Compound Name	Units	Reference Comment
Fentanyl	ng/mL	

10051B Postmortem Toxicology - Basic with Vitreous Alcohol Confirmation, Blood (Forensic) (CSA)

Summary of Changes: Specimen Requirements were changed.
Stability was changed.
Scope of Analysis was changed.
Order of Reporting was changed.

Test Updates

Test Changes

Specimen Requirements:	6 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	In addition to blood, collect 1 mL of Vitreous fluid for the Alcohol Confirmation. Collect sample using alcohol free skin preparation.
Rejection Criteria:	Received Room Temperature.
Stability:	Room Temperature: 1 day(s) Refrigerated: 10 day(s) Frozen (-20 °C): Undetermined
Scope of Analysis: Method (CPT Code)	ELISA (80101x11): Opiates, Cocaine / Metabolites, Benzodiazepines, Cannabinoids, Amphetamines, Barbiturates, Methadone, Phencyclidine, Methamphetamine, Oxycodone, Buprenorphine / Metabolite Headspace GC (82055): Ethanol, Blood Alcohol Concentration (BAC), Methanol, Isopropanol, Acetone

8041B Postmortem Toxicology - Basic with Vitreous Alcohol Confirmation, Blood (Forensic)

Summary of Changes:	Specimen Requirements were changed. Stability was changed. Scope of Analysis was changed. Order of Reporting was changed.

Specimen Requirements:	6 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	In addition to blood, collect 1 mL of Vitreous fluid for the Alcohol Confirmation. Collect sample using alcohol free skin preparation.
Rejection Criteria:	Received Room Temperature.
Stability:	Room Temperature: 1 day(s) Refrigerated: 10 day(s) Frozen (-20 °C): Undetermined
Scope of Analysis: Method (CPT Code)	ELISA (80101x12): Opiates, Cocaine / Metabolites, Benzodiazepines, Cannabinoids, Amphetamines, Barbiturates, Methadone, Phencyclidine, Fentanyl, Methamphetamine, Oxycodone, Buprenorphine / Metabolite Headspace GC (82055): Ethanol, Blood Alcohol Concentration (BAC), Methanol, Isopropanol, Acetone

8056B Postmortem Toxicology - Basic with Vitreous Alcohol Confirmation, Blood - University of MI (CSA)

Summary of Changes:	Specimen Requirements were changed. Stability was changed. Scope of Analysis was changed. Order of Reporting was changed.

Test Updates

Test Changes

Specimen Requirements:	6 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	In addition to blood, collect 1 mL of Vitreous fluid for the Alcohol Confirmation. Collect sample using alcohol free skin preparation.
Rejection Criteria:	Received Room Temperature.
Stability:	Room Temperature: 1 day(s) Refrigerated: 10 day(s) Frozen (-20 °C): Undetermined
Scope of Analysis: Method (CPT Code)	ELISA (80101x12): Opiates, Cocaine / Metabolites, Benzodiazepines, Cannabinoids, Amphetamines, Barbiturates, Methadone, Phencyclidine, Fentanyl, Methamphetamine, Oxycodone, Buprenorphine / Metabolite Headspace GC (82055): Ethanol, Blood Alcohol Concentration (BAC), Methanol, Isopropanol, Acetone

10055B Postmortem Toxicology - Basic, Blood (Forensic) (CSA)

Summary of Changes:	Specimen Requirements were changed. Stability was changed. Scope of Analysis was changed. Order of Reporting was changed. Methods/CPT Codes were changed [ELISA (80101x12)]

Specimen Requirements:	6 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	Collect sample using alcohol free skin preparation.
Rejection Criteria:	Received Room Temperature.
Stability:	Room Temperature: 1 day(s) Refrigerated: 10 day(s) Frozen (-20 °C): Undetermined
Scope of Analysis: Method (CPT Code)	ELISA (80101x12): Opiates, Cocaine / Metabolites, Benzodiazepines, Cannabinoids, Amphetamines, Barbiturates, Methadone, Phencyclidine, Fentanyl, Methamphetamine, Oxycodone, Buprenorphine / Metabolite Headspace GC (82055): Ethanol, Blood Alcohol Concentration (BAC), Methanol, Isopropanol, Acetone

8051B Postmortem Toxicology - Basic, Blood (Forensic)

Summary of Changes:	Specimen Requirements were changed. Stability was changed. Scope of Analysis was changed. Order of Reporting was changed.

Test Updates

Test Changes

Specimen Requirements:	6 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	Collect sample using alcohol free skin preparation.
Rejection Criteria:	Received Room Temperature.
Stability:	Room Temperature: 1 day(s) Refrigerated: 10 day(s) Frozen (-20 °C): Undetermined
Scope of Analysis: Method (CPT Code)	ELISA (80101x12): Opiates, Cocaine / Metabolites, Benzodiazepines, Cannabinoids, Amphetamines, Barbiturates, Methadone, Phencyclidine, Fentanyl, Methamphetamine, Oxycodone, Buprenorphine / Metabolite Headspace GC (82055): Ethanol, Blood Alcohol Concentration (BAC), Methanol, Isopropanol, Acetone

8051FL Postmortem Toxicology - Basic, Fluid (Forensic)

Summary of Changes:	Specimen Requirements were changed. Scope of Analysis was changed. Order of Reporting was changed.

Specimen Requirements:	7 mL Fluid
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Scope of Analysis: Method (CPT Code)	ELISA (80101x12): Opiates, Cocaine / Metabolites, Benzodiazepines, Cannabinoids, Amphetamines, Barbiturates, Methadone, Phencyclidine, Propoxyphene, Methamphetamine, Oxycodone, Buprenorphine / Metabolite Headspace GC (82055): Ethanol, Methanol, Isopropanol, Acetone

8051SP Postmortem Toxicology - Basic, Serum/Plasma (Forensic)

Summary of Changes:	Specimen Requirements were changed. Scope of Analysis was changed. Fentanyl was added. Propoxyphene was removed.

Test Updates

Test Changes

Specimen Requirements:	6 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Submit with Chain of Custody. Serum: Collect sample in Red top tube. Plasma: Collect sample in Gray top tube (Sodium Fluoride / Potassium Oxalate). Collect sample using alcohol free skin preparation. Promptly centrifuge and separate Serum or Plasma into an plastic screw capped vial using approved guidelines.
Rejection Criteria:	Received Room Temperature. Polymer gel separation tube (SST or PST).
Scope of Analysis: Method (CPT Code)	ELISA (80101x11): Opiates, Cocaine / Metabolites, Benzodiazepines, Cannabinoids, Amphetamines, Barbiturates, Methadone, Phencyclidine, Methamphetamine, Oxycodone, Buprenorphine / Metabolite Headspace GC (82055): Ethanol, Methanol, Isopropanol, Acetone ELISA (80101): Fentanyl

Compound Name	Units	Reference Comment
Fentanyl	ng/mL	

8051TI Postmortem Toxicology - Basic, Tissue (Forensic)

Summary of Changes:	Scope of Analysis was changed. Order of Reporting was changed.
Scope of Analysis: Method (CPT Code)	ELISA (80103, 80101x12): Opiates, Cocaine / Metabolites, Benzodiazepines, Cannabinoids, Amphetamines, Barbiturates, Methadone, Phencyclidine, Propoxyphene, Methamphetamine, Oxycodone, Buprenorphine / Metabolite Headspace GC (82055, 80103): Ethanol, Methanol, Isopropanol, Acetone

8051U Postmortem Toxicology - Basic, Urine (Forensic)

Summary of Changes:	Specimen Requirements were changed. Scope of Analysis was changed. Fentanyl was added. Propoxyphene was removed.

Specimen Requirements:	10 mL Urine
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Scope of Analysis: Method (CPT Code)	EIA (80101x9): Opiates, Cocaine / Metabolites, Benzodiazepines, Cannabinoids, Barbiturates, Methadone, Phencyclidine, Oxycodone Headspace GC (82055): Ethanol, Methanol, Isopropanol, Acetone IA (80101): Buprenorphine / Metabolite EIA (80101x2): Amphetamines, MDMA ELISA (80101): Fentanyl

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Fentanyl	ng/mL	

9334FL Propoxyphene Screen, Fluid

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements: 4 mL Fluid
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None

4029B Psilocybin as Psilocin (Qualitative), Blood

Summary of Changes: Methods/CPT Codes were changed [LC-MS/MS (83788)]

Scope of Analysis: Method (CPT Code): LC-MS/MS (83788): Psilocin

4029SP Psilocybin as Psilocin (Qualitative), Serum/Plasma

Summary of Changes: Methods/CPT Codes were changed [LC-MS/MS (83788)]

Scope of Analysis: Method (CPT Code): LC-MS/MS (83788): Psilocin

4029U Psilocybin as Psilocin (Qualitative), Urine

Summary of Changes: Methods/CPT Codes were changed [LC-MS/MS (83788)]

Scope of Analysis: Method (CPT Code): LC-MS/MS (83788): Psilocin

4127B Suboxone® - Free, Blood

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.
Scope of Analysis was changed.
Order of Reporting was changed.
Reference Comment was changed.

Test Updates

Test Changes

Specimen Requirements:	2 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Stability:	Room Temperature: 14 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (83925): Buprenorphine - Free, Naloxone - Free, Norbuprenorphine - Free

Compound Name	Units	Reference Comment
Buprenorphine - Free	ng/mL	Suboxone® is available as sublingual tablets containing Buprenorphine (BUP) and Naloxone (NAL) in a 4:1 ratio. There are two dosage forms: 2 mg BUP: 0.5 mg NAL and 8 mg BUP: 2 mg NAL. Following a single dose of Suboxone® mean maximum plasma Buprenorphine concentrations (+/- 1 S.D.) were: 4 mg BUP: 1 mg NAL: 2.33 +/- 0.80 ng/mL 8 mg BUP: 2 mg NAL: 3.53 +/- 1.16 ng/mL 16 mg BUP: 4 mg NAL: 5.83 +/- 2.09 ng/mL 24 mg BUP: 6 mg NAL: 6.44 +/- 2.10 ng/mL The blood to plasma ratio of buprenorphine is approximately 1.0 – 1.4.

4127SP Suboxone® - Free, Serum/Plasma

Summary of Changes:	Stability was changed. Scope of Analysis was changed. Order of Reporting was changed.
Stability:	Room Temperature: 13 day(s) Refrigerated: 29 day(s) Frozen (-20 °C): 29 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (83925): Buprenorphine - Free, Naloxone - Free, Norbuprenorphine - Free

54334B Synthetic Opioids - Free (Unconjugated) Confirmation (Drug Impaired Driving/DRE Toxicology), Blood (Forensic)

Test Updates

Test Changes

Summary of Changes:	Test Name was changed. Specimen Requirements (Specimen Container) were changed. Specimen Requirements (Rejection Criteria) were changed. Stability was changed. Methods/CPT Codes were changed [LC-MS/MS (83925)]

Specimen Requirements:	2 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Stability:	Room Temperature: 14 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (83925): Buprenorphine - Free, Norbuprenorphine - Free, Butorphanol - Free, Nalbuphine - Free

54334SP Synthetic Opioids - Free (Unconjugated) Confirmation (Drug Impaired Driving/DRE Toxicology), Serum/Plasma (Forensic)

Summary of Changes:	Test Name was changed. Specimen Requirements were changed. Stability was changed. Methods/CPT Codes were changed [LC-MS/MS (83925)]

Specimen Requirements:	2 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: 29 day(s) Refrigerated: 29 day(s) Frozen (-20 °C): 29 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (83925): Buprenorphine - Free, Norbuprenorphine - Free, Butorphanol - Free, Nalbuphine - Free

52196B Synthetic Opioids - Free (Unconjugated) Confirmation, Blood (Forensic) (CSA)

Test Updates

Test Changes

Summary of Changes: Test Name was changed.
Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.
Reference Comment was changed.

Specimen Requirements: 2 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 14 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code): LC-MS/MS (83925): Buprenorphine - Free, Norbuprenorphine - Free

Compound Name	Units	Reference Comment
Buprenorphine - Free	ng/mL	Maximum plasma buprenorphine concentrations in patients maintained on varying buprenorphine doses were: 2 mg/day: 0.3 +/- 0.1 ng/mL 16 mg/day: 6.3 +/- 0.9 ng/mL 32 mg/day: 13 +/- 4.2 ng/mL The blood to plasma ratio of buprenorphine is approximately 1.0 - 1.4.
Norbuprenorphine - Free	ng/mL	Maximum plasma norbuprenorphine concentrations in patients maintained on varying buprenorphine doses were: 2 mg/day: 0.7 +/- 0.2 ng/mL 16 mg/day: 5.4 +/- 1.3 ng/mL 32 mg/day: 14 +/- 2.9 ng/mL The blood to plasma ratio for norbuprenorphine is not known.

52092B Synthetic Opioids - Free (Unconjugated) Confirmation, Blood (Forensic)

Summary of Changes: Test Name was changed.
Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Scope of Analysis was changed.
Reference Comment was changed.
Hydromorphone - Free, Morphine - Free, Nalbuphine - Free and Naloxone - Free were removed.

Test Updates

Test Changes

Specimen Requirements:	2 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Stability:	Room Temperature: 14 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (83925): Naltrexone - Free, Butorphanol - Free

Compound Name	Units	Reference Comment
Naltrexone - Free	ng/mL	The peak plasma concentrations at approximately one hour following a single oral dose of naltrexone were: 9 (+/- 5) ng/mL after 50 mg 20 (+/- 18) ng/mL after 100 mg 36 (+/- 20) ng/mL after 200 mg The average peak plasma concentration of naltrexone was 28 ng/mL following four doses of 380 mg naltrexone given by depot intramuscular injection every 28 days. The blood to plasma ratio of naltrexone is approximately 0.9.
Butorphanol - Free	ng/mL	Peak plasma concentrations following 1 to 2 mg doses of butorphanol by intravenous, intramuscular or intranasal routes range from 1 to 4 ng/mL. The blood to plasma ratio of butorphanol is approximately 1.2.

52407B Synthetic Opioids - Free (Unconjugated) Confirmation, Blood (Forensic)

Summary of Changes:	Test Name was changed. Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Specimen Requirements (Rejection Criteria) were changed. Stability was changed. Reference Comment was changed.

Specimen Requirements:	2 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None

Test Updates

Test Changes

Stability: Room Temperature: 14 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

Scope of Analysis: LC-MS/MS (83925): Buprenorphine - Free, Norbuprenorphine - Free, Butorphanol -
Method (CPT Code) Free, Nalbuphine - Free

Compound Name	Units	Reference Comment
Buprenorphine - Free	ng/mL	Maximum plasma buprenorphine concentrations in patients maintained on varying buprenorphine doses were: 2 mg/day: 0.3 +/- 0.1 ng/mL 16 mg/day: 6.3 +/- 0.9 ng/mL 32 mg/day: 13 +/- 4.2 ng/mL The blood to plasma ratio of buprenorphine is approximately 1.0 - 1.4.
Norbuprenorphine - Free	ng/mL	Maximum plasma norbuprenorphine concentrations in patients maintained on varying buprenorphine doses were: 2 mg/day: 0.7 +/- 0.2 ng/mL 16 mg/day: 5.4 +/- 1.3 ng/mL 32 mg/day: 14 +/- 2.9 ng/mL The blood to plasma ratio for norbuprenorphine is not known.
Butorphanol - Free	ng/mL	Peak plasma concentrations following 1 to 2 mg doses of butorphanol by intravenous, intramuscular or intranasal routes range from 1 to 4 ng/mL. The blood to plasma ratio of butorphanol is approximately 1.2.
Nalbuphine - Free	ng/mL	The average peak plasma concentration was 53 ng/mL nalbuphine 5 minutes after a 10 mg intravenous dose. The blood to plasma ratio of nalbuphine is approximately 0.9 to 1.0.

52448B Synthetic Opioids - Free (Unconjugated) Confirmation, Blood (Forensic)

Summary of Changes: Test Name was changed.
Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Reference Comment was changed.

Test Updates

Test Changes

Specimen Requirements:	2 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (83925): Butorphanol - Free, Nalbuphine - Free

Compound Name	Units	Reference Comment
Butorphanol - Free	ng/mL	Peak plasma concentrations following 1 to 2 mg doses of butorphanol by intravenous, intramuscular or intranasal routes range from 1 to 4 ng/mL. The blood to plasma ratio of butorphanol is approximately 1.2.
Nalbuphine - Free	ng/mL	The average peak plasma concentration was 53 ng/mL nalbuphine 5 minutes after a 10 mg intravenous dose. The blood to plasma ratio of nalbuphine is approximately 0.9 to 1.0.

53092B Synthetic Opioids - Free (Unconjugated) Confirmation, Blood (Forensic)

Summary of Changes:	Test Name was changed. Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Stability was changed. Scope of Analysis was changed. Reference Comment was changed. Hydromorphone - Free, Morphine - Free, Nalbuphine - Free and Naloxone - Free were removed.

Specimen Requirements:	2 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Stability:	Room Temperature: 14 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)

Test Updates

Test Changes

Scope of Analysis: Method (CPT Code): LC-MS/MS (83925): Naltrexone - Free, Butorphanol - Free

Compound Name	Units	Reference Comment
Naltrexone - Free	ng/mL	The peak plasma concentrations at approximately one hour following a single oral dose of naltrexone were: 9 (+/- 5) ng/mL after 50 mg 20 (+/- 18) ng/mL after 100 mg 36 (+/- 20) ng/mL after 200 mg The average peak plasma concentration of naltrexone was 28 ng/mL following four doses of 380 mg naltrexone given by depot intramuscular injection every 28 days. The blood to plasma ratio of naltrexone is approximately 0.9.
Butorphanol - Free	ng/mL	Peak plasma concentrations following 1 to 2 mg doses of butorphanol by intravenous, intramuscular or intranasal routes range from 1 to 4 ng/mL. The blood to plasma ratio of butorphanol is approximately 1.2.

52092FL Synthetic Opioids - Free (Unconjugated) Confirmation, Fluid (Forensic)

Summary of Changes: Test Name was changed.
Specimen Requirements were changed.
Scope of Analysis was changed.
Hydromorphone - Free, Morphine - Free, Nalbuphine - Free and Naloxone - Free were removed.

Specimen Requirements: 2 mL Fluid
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Scope of Analysis: Method (CPT Code): LC-MS/MS (83925): Naltrexone - Free, Butorphanol - Free

53092FL Synthetic Opioids - Free (Unconjugated) Confirmation, Fluid (Forensic)

Summary of Changes: Test Name was changed.
Specimen Requirements were changed.
Scope of Analysis was changed.
Hydromorphone - Free, Morphine - Free, Nalbuphine - Free and Naloxone - Free were removed.

Test Updates

Test Changes

Specimen Requirements:	2 mL Fluid
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Scope of Analysis: Method (CPT Code)	LC-MS/MS (83925): Naltrexone - Free, Butorphanol - Free

52092SP Synthetic Opioids - Free (Unconjugated) Confirmation, Serum/Plasma (Forensic)

Summary of Changes:	Test Name was changed. Stability was changed. Scope of Analysis was changed. Reference Comment was changed. Hydromorphone - Free, Morphine - Free, Nalbuphine - Free and Naloxone - Free were removed.
Stability:	Room Temperature: 13 day(s) Refrigerated: 29 day(s) Frozen (-20 °C): 29 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (83925): Naltrexone - Free, Butorphanol - Free

Compound Name	Units	Reference Comment
Naltrexone - Free	ng/mL	The peak plasma concentrations at approximately one hour following a single oral dose of naltrexone were: 9 (+/- 5) ng/mL after 50 mg 20 (+/- 18) ng/mL after 100 mg 36 (+/- 20) ng/mL after 200 mg The average peak plasma concentration of naltrexone was 28 ng/mL following four doses of 380 mg naltrexone given by depot intramuscular injection every 28 days.
Butorphanol - Free	ng/mL	Peak plasma concentrations following 1 to 2 mg doses of butorphanol by intravenous, intramuscular or intranasal routes range from 1 to 4 ng/mL.

52407SP Synthetic Opioids - Free (Unconjugated) Confirmation, Serum/Plasma (Forensic)

Summary of Changes:	Test Name was changed. Specimen Requirements were changed. Stability was changed. Reference Comment was changed.

Test Updates

Test Changes

Specimen Requirements:	2 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: 29 day(s) Refrigerated: 29 day(s) Frozen (-20 °C): 29 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (83925): Buprenorphine - Free, Norbuprenorphine - Free, Butorphanol - Free, Nalbuphine - Free

Compound Name	Units	Reference Comment
Buprenorphine - Free	ng/mL	Maximum plasma buprenorphine concentrations in patients maintained on varying buprenorphine doses were: 2 mg/day: 0.3 +/- 0.1 ng/mL 16 mg/day: 6.3 +/- 0.9 ng/mL 32 mg/day: 13 +/- 4.2 ng/mL
Norbuprenorphine - Free	ng/mL	Maximum plasma norbuprenorphine concentrations in patients maintained on varying buprenorphine doses were: 2 mg/day: 0.7 +/- 0.2 ng/mL 16 mg/day: 5.4 +/- 1.3 ng/mL 32 mg/day: 14 +/- 2.9 ng/mL
Butorphanol - Free	ng/mL	Peak plasma concentrations following 1 to 2 mg doses of butorphanol by intravenous, intramuscular or intranasal routes range from 1 to 4 ng/mL.
Nalbuphine - Free	ng/mL	The average peak plasma concentration was 53 ng/mL nalbuphine 5 minutes after a 10 mg intravenous dose.

52448SP Synthetic Opioids - Free (Unconjugated) Confirmation, Serum/Plasma (Forensic)

Summary of Changes:	Test Name was changed. Specimen Requirements were changed. Stability was changed. Reference Comment was changed.

Test Updates

Test Changes

Specimen Requirements:	2 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: 29 day(s) Refrigerated: 29 day(s) Frozen (-20 °C): 29 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (83925): Butorphanol - Free, Nalbuphine - Free

Compound Name	Units	Reference Comment
Butorphanol - Free	ng/mL	Peak plasma concentrations following 1 to 2 mg doses of butorphanol by intravenous, intramuscular or intranasal routes range from 1 to 4 ng/mL.
Nalbuphine - Free	ng/mL	The average peak plasma concentration was 53 ng/mL nalbuphine 5 minutes after a 10 mg intravenous dose.

53092SP Synthetic Opioids - Free (Unconjugated) Confirmation, Serum/Plasma (Forensic)

Summary of Changes:	Test Name was changed. Stability was changed. Scope of Analysis was changed. Reference Comment was changed. Hydromorphone - Free, Morphine - Free, Nalbuphine - Free and Naloxone - Free were removed.
Stability:	Room Temperature: 13 day(s) Refrigerated: 29 day(s) Frozen (-20 °C): 29 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (83925): Naltrexone - Free, Butorphanol - Free

Compound Name	Units	Reference Comment
Naltrexone - Free	ng/mL	The peak plasma concentrations at approximately one hour following a single oral dose of naltrexone were: 9 (+/- 5) ng/mL after 50 mg 20 (+/- 18) ng/mL after 100 mg 36 (+/- 20) ng/mL after 200 mg The average peak plasma concentration of naltrexone was 28 ng/mL following four doses of 380 mg naltrexone given by depot intramuscular injection every 28 days.

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Butorphanol - Free	ng/mL	Peak plasma concentrations following 1 to 2 mg doses of butorphanol by intravenous, intramuscular or intranasal routes range from 1 to 4 ng/mL.

4303SP Talwin® Nx, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 13 day(s)
Refrigerated: 29 day(s)
Frozen (-20 °C): 29 day(s)

Test Updates

Discontinued Tests

Test Code	Test Name	Alternative Test
8079B	Drug Impaired Driving/DRE Toxicology Low Dose Opiates Add-On, Blood (Forensic)	8075B - Drug Impaired Driving/DRE Toxicology Expanded Drug Screen Add-On, Blood (Forensic)
8079U	Drug Impaired Driving/DRE Toxicology Low Dose Opiates Add-On, Urine (Forensic)	8075U - Drug Impaired Driving/DRE Toxicology Expanded Drug Screen Add-On, Urine (Forensic)
1912SP	Embeda®, Serum/Plasma	8666SP - Morphine - Free (Unconjugated), Serum/Plasma
1912U	Embeda®, Urine	8666U - Morphine - Free (Unconjugated), Urine
3113B	Naloxone - Free (Unconjugated) Screen, Blood	3111B - Naloxone - Free (Unconjugated), Blood
3113FL	Naloxone - Free (Unconjugated) Screen, Fluid	3111B - Naloxone - Free (Unconjugated), Blood
3113SP	Naloxone - Free (Unconjugated) Screen, Serum/Plasma	3111SP - Naloxone - Free (Unconjugated), Serum/Plasma
3113TI	Naloxone - Free (Unconjugated) Screen, Tissue	3111B - Naloxone - Free (Unconjugated), Blood
3115B	Naltrexone and Metabolite - Free (Unconjugated) Screen, Blood	3116B - Naltrexone and Metabolite - Free (Unconjugated), Blood
3115SP	Naltrexone and Metabolite - Free (Unconjugated) Screen, Serum/Plasma	3116SP - Naltrexone and Metabolite - Free (Unconjugated), Serum/Plasma
3115U	Naltrexone and Metabolite - Total (Conjugated/Unconjugated) Screen, Urine	3116U - Naltrexone and Metabolite - Total (Conjugated/Unconjugated), Urine
3237B	Opiates (Low Dose) - Free (Unconjugated) Screen, Blood	3116B - Naltrexone and Metabolite - Free (Unconjugated), Blood 0801B - Buprenorphine and Metabolite - Free (Unconjugated), Blood 3111B - Naloxone - Free (Unconjugated), Blood 3110B - Nalbuphine - Free (Unconjugated), Blood 0885B - Butorphanol - Free (Unconjugated), Blood 8664B - Hydromorphone - Free (Unconjugated), Blood 8666B - Morphine - Free (Unconjugated), Blood

Test Updates

Discontinued Tests

Test Code	Test Name	Alternative Test
3237SP	Opiates (Low Dose) - Free (Unconjugated) Screen, Serum/Plasma	3116SP - Naltrexone and Metabolite - Free (Unconjugated), Serum/Plasma 0801SP - Buprenorphine and Metabolite - Free (Unconjugated), Serum/Plasma 3111SP - Naloxone - Free (Unconjugated), Serum/Plasma 3110SP - Nalbuphine - Free (Unconjugated), Serum/Plasma 0885SP - Butorphanol - Free (Unconjugated), Serum/Plasma 8664SP - Hydromorphone - Free (Unconjugated), Serum/Plasma 8666SP - Morphine - Free (Unconjugated), Serum/Plasma
3237TI	Opiates (Low Dose) - Free (Unconjugated) Screen, Tissue	3116B - Naltrexone and Metabolite - Free (Unconjugated), Blood 0801B - Buprenorphine and Metabolite - Free (Unconjugated), Blood 3111B - Naloxone - Free (Unconjugated), Blood 3110B - Nalbuphine - Free (Unconjugated), Blood 0885B - Butorphanol - Free (Unconjugated), Blood 8664B - Hydromorphone - Free (Unconjugated), Blood 8666B - Morphine - Free (Unconjugated), Blood
3237U	Opiates (Low Dose) - Total (Conjugated/Unconjugated) Screen, Urine	3116U - Naltrexone and Metabolite - Total (Conjugated/Unconjugated), Urine 0801U - Buprenorphine and Metabolite - Total (Conjugated/Unconjugated), Urine 3111U - Naloxone - Total (Conjugated/Unconjugated), Urine 3110U - Nalbuphine - Total (Conjugated/Unconjugated) Screen, Urine 0885U - Butorphanol - Total (Conjugated/Unconjugated) Screen, Urine 8664U - Hydromorphone - Total (Conjugated/Unconjugated), Urine 8666U - Morphine - Free (Unconjugated), Urine